PCSK9 and metabolic dysfunction-associated steatohepatitis: It is also unclear if the etiology of liver disease in this cohort (HBV, n = 14; HCV, n = 15; ethanol abuse; n = 3; non-alcoholic steatohepatitis (NASH), n = 4; other etiologies, n = 3) impacts hepatic PCSK9 expression, secretion and/or PCSK9 circulation [20].